Your browser is no longer supported. Please, upgrade your browser.
ADGI [NASD]
Adagio Therapeutics, Inc.
Index- P/E- EPS (ttm)-14.74 Insider Own26.90% Shs Outstand61.30M Perf Week19.58%
Market Cap645.79M Forward P/E- EPS next Y-3.25 Insider Trans0.00% Shs Float51.73M Perf Month-38.87%
Income- PEG- EPS next Q-1.03 Inst Own65.40% Short Float13.96% Perf Quarter-81.31%
Sales- P/S- EPS this Y- Inst Trans9.63% Short Ratio0.90 Perf Half Y-
Book/sh10.33 P/B0.61 EPS next Y-44.40% ROA- Target Price8.33 Perf Year-
Cash/sh6.49 P/C0.97 EPS next 5Y- ROE- 52W Range4.92 - 78.82 Perf YTD-13.36%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-92.02% Beta-
Dividend %- Quick Ratio12.80 Sales past 5Y- Gross Margin- 52W Low27.85% ATR2.05
Employees68 Current Ratio12.80 Sales Q/Q- Oper. Margin- RSI (14)36.64 Volatility15.11% 12.67%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.38 Prev Close6.44
ShortableYes LT Debt/Eq0.00 EarningsNov 15 BMO Payout- Avg Volume8.03M Price6.29
Recom3.00 SMA20-8.03% SMA50-65.08% SMA200-77.13% Volume3,084,168 Change-2.33%
Jan-06-22Downgrade Morgan Stanley Overweight → Underweight
Dec-22-21Downgrade Jefferies Buy → Hold $46 → $10
Dec-15-21Downgrade Stifel Buy → Hold $50 → $9
Dec-15-21Downgrade Guggenheim Buy → Neutral
Nov-29-21Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $49
Aug-31-21Initiated Stifel Buy $57
Aug-31-21Initiated Morgan Stanley Equal-Weight $33
Aug-31-21Initiated Jefferies Buy $60
Aug-31-21Initiated Guggenheim Buy $40
Jan-20-22 05:05PM  
Jan-13-22 07:08AM  
Jan-12-22 04:57PM  
Jan-06-22 06:30AM  
Dec-29-21 05:30AM  
Dec-24-21 12:38AM  
Dec-22-21 07:17PM  
11:11AM  
08:21AM  
Dec-21-21 01:38AM  
Dec-18-21 12:38AM  
Dec-17-21 08:00AM  
Dec-16-21 11:38PM  
04:13PM  
02:38PM  
07:54AM  
Dec-15-21 01:50PM  
10:24AM  
Dec-14-21 04:11PM  
12:41PM  
12:39PM  
11:16AM  
10:56AM  
07:00AM  
06:51AM  
Dec-11-21 05:38AM  
Dec-09-21 08:38AM  
Dec-08-21 03:16PM  
05:57AM  
Dec-07-21 10:15AM  
Dec-04-21 07:52AM  
Dec-03-21 12:34PM  
Dec-02-21 08:38AM  
Nov-30-21 04:15PM  
12:00PM  
09:37AM  
08:59AM  
08:00AM  
Nov-29-21 02:16PM  
01:05PM  
01:01PM  
06:39AM  
06:30AM  
Nov-22-21 06:30AM  
Nov-15-21 06:30AM  
Nov-10-21 06:30AM  
Nov-06-21 08:10AM  
Oct-19-21 08:31AM  
06:30AM  
Oct-04-21 10:54AM  
05:20AM  
Oct-01-21 12:41PM  
Sep-29-21 09:33AM  
06:30AM  
06:30AM  
Aug-10-21 04:22PM  
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Its lead product candidate is the ADG20, a neutralizing antibody that is in Phase II/III clinical trials for the treatment and prevention of coronavirus disease. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. Adagio Therapeutics, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.